BACKGROUND: Previous studies have shown the presence of serum anti-nuclear (ANA), anti-smooth muscle (SMA), anti-mitochondrial (AMA), anti-gastric parietal cell (GPCA), anti-thyroglobulin (TGA) and anti-thyroid microsomal autoantibodies (TMA) in small groups of patients with oral lichen planus (OLP). METHODS: In this study, the serum levels of ANA, SMA, AMA, GPCA, TGA and TMA were measured in a group of 320 Chinese OLP patients and 53 healthy control subjects to assess whether Chinese OLP patients had significantly higher frequencies of serum autoantibodies than healthy control subjects and to assess which risk factors had a significant influence on the possession of a specific serum autoantibody in OLP patients. RESULTS: We found that autoantibodies were present in 195 (60.9%) of the 320 OLP patients. The frequencies of presence of serum ANA (28.1%), GPCA (26.3%), TGA (21.3%) and TMA (24.4%) in OLP patients were significantly higher than those (5.7%, 1.9%, 1.9% and 1.9%, respectively) in healthy control subjects (all P-values were < 0.005). Forty-one (12.8%) OLP patients also had antihepatitis C virus antibody (HCVA) in their sera. The multivariate logistic regression found that major erosive OLP (EOLP) [odds ratio (OR) = 1.786], TGA ⁄ TMA-positivity (OR = 2.517), and HCVA-positivity (OR = 2.214) were significant risk factors to influence ANA-positivity in OLP patients. Moreover, only major EOLP (OR = 1.879) and ANA-positivity (OR = 2.581) were significant risk factors to influence TGA ⁄ TMA-positivity in OLP patients. CONCLUSIONS: There are significantly higher frequencies of presence of ANA, GPCA, TGA and TMA in Chinese OLP patients than in healthy control subjects.
Introduction
Oral lichen planus (OLP) is a chronic inflammatory oral mucosal disease. Previous study showed involvement of both antigen-specific and non-specific mechanisms in OLP. Antigen-specific mechanisms include antigen presentation by basal keratinocytes and antigen-specific keratinocyte killing by CD8 + cytotoxic T lymphocytes. Non-specific mechanisms include mast cell degranulation and matrix metalloproteinase activation in OLP lesions (1) . Through mast cell ⁄ T-cell interactions in OLP lesions, mast cell-released cytokines, chemokines and matrix metalloproteinases can promote T-cell activation, migration, proliferation and differentiation (2) . OLP is histologically characterized by liquefaction degeneration of basal epithelial cells and an intraepithelial and subepithelial infiltrate of mononuclear cells which are predominantly CD8 + . CD4 + cells are observed mainly in the deep lamina propria (3) . An increase in histocompatibility leukocyte antigen (HLA)-D-related (DR)-positive CD3 + cells in both the local lesional tissues and peripheral lymphocytes also indicates T-cell activation in OLP (4, 5) . The above findings suggest that OLP is a T-cell-mediated inflammatory disease.
Previous studies have shown the presence of serum autoantibodies including anti-epithelial cell, anti-nuclear (ANA), anti-smooth muscle (SMA), anti-mitochondrial (AMA), anti-gastric parietal cell (GPCA), anti-thyroglobulin (TGA), anti-thyroid microsomal (TMA) and anti-desmogleins 1 and 3 antibodies in small groups of OLP patients (all studies n < 33 except ours n = 63) (6) (7) (8) (9) (10) (11) . In this study, we examined the frequencies of presence of serum antoantibodies including ANA, SMA, AMA, GPCA, TGA and TMA in a large group of 320 Chinese OLP patients and in 53 healthy control subjects. We tried to find whether there were significantly higher frequencies of presence of serum autoantibodies in Chinese OLP patients than in healthy control subjects. In addition, we also used univariate and multivariate analyses to assess which risk factors had a significant influence on the possession of a specific serum autoantibody in OLP patients.
Materials and methods

Subjects
The study group consisted of 320 OLP patients (53 men and 267 women, age range 21-83 years, mean 55.3 years) without LP of other mucosal or skin surfaces. The normal control group consisted of 53 healthy subjects (eight men and 45 women, age range 21-83 years, mean 54.7 years) without any oral mucosal or systemic diseases. All the patients and control subjects were seen consecutively, diagnosed, and treated in the Department of Oral Diagnosis of National Taiwan University Hospital from July 2004 to June 2007. OLP patients with areca quid chewing habit, hypertension and autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, pemphigus vulgaris and cicatricial pemphigoid were excluded. In addition, none of them had taken any prescription medication at least 3 months before entering the study. The 320 OLP patients included 292 (50 men and 242 women, age range 21-83 years, mean 55.5 years) with erosive OLP (EOLP) and 28 (three men and 25 women, age range 24-83 years, mean 52.8 years) with non-erosive OLP (NEOLP). They were selected according to the following criteria: (i) a typical clinical presentation of radiating grayish-white Wickham striae, papules and plaques, separately or in combination (NEOLP), and erosion or ulceration on the oral mucosa (EOLP) and (ii) biopsy specimens characteristic of OLP, that is, hyperkeratosis or parakeratosis, a slightly acanthotic epithelium with liquefaction degeneration of the basal epithelial cells, a pronounced band-like lymphocytic infiltrate in the lamina propria, and the absence of epithelial dysplasia. The EOLP was further divided into the major and minor types according to criteria described previously (12) . The blood samples were drawn from OLP patients and healthy control subjects. The serum autoantibody, anti-hepatitis C virus antibody (HCVA) and blood glucose levels were determined. This study was reviewed and approved by the Human Investigation Review Committee at the National Taiwan University Hospital.
Determination of serum autoantibody levels
The circulating ANA, SMA, AMA and GPCA were detected by the indirect immunofluorescence technique with HEp-2 cells (Medical & Biological Laboratories Co., Nagaya, Japan; for ANA), rat kidney (for SMA and AMA) and rat stomach (for GPCA) as substrates as described previously (10, 13) . In brief, HEp-2 cells or 5 lm-thick cryostat sections of substrate tissues on slides were reacted with serially diluted OLP patients' and control subjects' sera in a moist chamber at room temperature for 30 min. The initial dilution of the patients' and control subjects' sera was 1:20 with PBS. After washing, the sections were incubated with fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG antiserum (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA) which had been pre-diluted and kept in dropper vial by the manufacturer and was readyto-use for another 30 min. The sections were washed again, mounted with buffered glycerine, and examined with an Olympus fluorescence microscope (Olympus, Tokyo, Japan). Sera were scored as positive when they produced fluorescence at a dilution of 160-fold or more for ANA, and of 20-fold or more for SMA, AMA and GPCA.
TGA and TMA titers were measured by a semiquantitative microtiter particle agglutination test using Serodia-AMC kits (Fujirebio Inc., Tokyo, Japan) as described previously (10, 13) . In brief, serial 2-fold dilutions of initial 1:20 dilutions of OLP patients' and control subjects' sera in the wells of a microtitration tray were reacted with gelatin particles sensitized with thyroglobulin or thyroid microsomal antigen at room temperature for 3 hr. The results were obtained by reading the settling patterns of the colored gelatin particles using a tray viewer. Serum containing TGA or TMA reacted with the thyroglobulin or thyroid microsomal antigen-sensitized colored gelatin particles to form a smooth mat of agglutinated particles in the microtitration tray. Negative reactions were characterized by a compact button formed by the settling of the non-agglutinated particles. TGA or TMA titers equal to or greater than 1:40 were considered positive.
Determination of HCVA level
The serum HCVA was detected by an ARCHITECT anti-HCV assay as described previously (14, 15) . This assay was an automated chemiluminescent microparticle immunoassay (CMIA) based on the enzyme immunoassay (EIA) principle. In contrast to the EIA, where the antigen-antibody complexes were detected by enzymelabeled conjugate, the CMIA used acridinium labeled conjugate as detection system. The resulting chemiluminescent reaction was measured as relative light units (RLUs). ARCHITECT Anti-HCV was designed to detect antibodies to structural and non-structural proteins of the HCV genome (NS3, NS4, core). The ARCHITECT Anti-HCV assay cutoff value was calculated by the following formula: calibrator 1 mean RLU value · 0.074 = cutoff RLU. ARCHITECT delivered specimen results as a ratio of the specimen signal (in RLU) to the cutoff value (S ⁄ CO). S ⁄ CO ratios of ‡ 1.00 were considered reactive for HCVA; ratios less than 1.00 were non-reactive for HCVA.
Diagnosis of diabetes mellitus
Patients with fasting plasma glucose levels more than 126 mg ⁄ ml on two or more tests on different days or a random blood glucose level of 200 mg ⁄ ml or higher were diagnosed as having diabetes mellitus (DM).
Statistical analysis
The difference in frequency of presence of each serum autoantibody was compared between any two groups by chi-square or Fisher's exact test, where appropriate. The multivariate logistic regression was used to assess which risk factors including the age, gender, OLP type (EOLP or NEOLP), EOLP type (major or minor), and the presence of other autoantibodies, HCVA or DM had a significant influence on the possession of a specific serum autoantibody in OLP patients. The result was considered to be significant if the P-value was less than 0.05.
Results
Autoantibodies were present in 195 (60.9%) of the 320 OLP patients: 104 (32.5%) had only one autoantibody, 44 (13.7%) two autoantibodies, 30 (9.4%) three autoantibodies, 16 (5.0%) four autoantibodies and 1 (0.3%) five autoantibodies. The frequencies of presence of ANA, SMA, AMA, GPCA, TGA and TMA in different groups of OLP patients and 53 healthy control subjects are shown in Table 1 . We found that the frequencies of presence of serum ANA (28.1%, P = 0.000), GPCA (26.3%, P = 0.000), TGA (21.3%, P = 0.002) and TMA (24.4%, P = 0.000) in OLP patients were significantly higher than the corresponding autoantibody frequencies (5.7%, 1.9%, 1.9% and 1.9%, respectively) in healthy control subjects. If the OLP patients were further divided into two subgroups according to the age, gender, and the presence of erosive lesion (EOLP or NEOLP), HCVA or DM, all subgroups of OLP patients also had significantly higher frequencies of presence of serum ANA, GPCA, TGA and TMA than healthy control subjects except the frequency of serum ANA in OLP patients £ 50 years of age (P = 0.059, marginal significance) and the frequency of serum TGA in male OLP patients (P = 0.118, Table 1) .
Of 320 OLP patients, 41 (12.8%) were also HCVApositive and 47 (14.7%) also had DM (Table 1) . Univariate analysis by chi-squared test showed a significant correlation between ANA-positivity and OLP patients with the age >50 years (P = 0.008), major EOLP (P = 0.000), or the presence of GPCA (P = 0.026), TGA ⁄ TMA (P = 0.000), or HCVA (P = 0.000) in their sera ( Table 2 ). The multivariate logistic regression found that major EOLP [odds ratio (OR) = 1.786, P = 0.033], TGA ⁄ TMA-positivity (OR = 2.517, P = 0.001) and HCVA-positivity (OR = 2.214, P = 0.030) were significant risk factors to influence ANA-positivity in OLP patients.
The GPCA-positivity in OLP patients was significantly associated with the presence of serum ANA (P = 0.026) or TGA ⁄ TMA (P = 0.026, Table 3 ), whereas neither of these two risk factors reached the significant level (both P-values = 0.070) to influence the GPCA-positivity in OLP patients by multivariate logistic regression. Furthermore, there was a significant correlation between the TGA ⁄ TMA-positivity and major EOLP (P = 0.000) or the presence of ANA 
Autoantibodies in OLP patients
(P = 0.000), GPCA (P = 0.026) or HCVA (P = 0.027) in OLP patients (Table 4 ). The multivariate logistic regression found that only major EOLP (OR = 1.879, P = 0.016) and ANA-positivity (OR = 2.581, P = 0.001) were significant risk factors to influence TGA ⁄ TMA-positivity in OLP patients. However, the presence of SMA or AMA in OLP patients was not related to the affecting factors such as the age, gender, OLP type, EOLP type, and the presence of other autoantibodies, HCVA or DM in OLP patients (Tables 5 and 6 ). We further calculated the overlap of serum autoantibodies in 320 OLP patients. If 320 OLP patients were divided into three subgroups according to the possession of organ-specific (GPCA or TGA ⁄ TMA) or non-organspecific (ANA ⁄ SMA ⁄ AMA) serum autoantibodies: 84 
Discussion
Previous studies demonstrated an overall incidence of 27-82% for the presence of serum autoantibodies in small groups of OLP or EOLP patients (6-11). Lin et al. (6) showed the presence of serum anti-basal cell antibodies (anti-BCA) in 54% (34 ⁄ 63) OLP patients. There is a decrease in the serum anti-BCA titers in six of eight anti-BCA-positive OLP patients after topical application of triamcinolone. Sun et al. . This study showed an overall incidence of 60.9% for the presence of serum autoantibodies in a large group of 320 OLP patients, significantly higher frequencies of presence of serum ANA, GPCA, TGA and TMA in OLP patients than in healthy control subjects, and incidences of approximately 33-51% overlap of organ-specific and nonorgan-specific serum autoantibodies in Chinese OLP patients with one or more organ-specific or non-organspecific serum autoantibodies. The above findings suggest that there are high frequencies of presence of serum autoantibodies in OLP patients and these autoantibodies may disappear after corticosteroid or immunomodulator treatment. The mechanisms for the induction and production of various autoantibodies in the sera of OLP patients are still not clear. The histology of OLP is characterized by liquefaction degeneration of basal epithelial cells and a subepithelial band-like infiltrate of majorly T lymphocytes and minorly B lymphocytes and macrophages (16) . T-cell activation in OLP has been indirectly proven by the increase in HLA-DR-positive CD3 + cells in both the local lesional tissues (4) and peripheral lymphocytes (5). Moreover, a significant increase of Langerhans cells is found in the epithelium and in the lamina propria of OLP lesion compared with normal oral mucosa (17) . The nuclear antigens released from the damaged basal epithelial cells might be modified by some unknown agents from the environment and phagocytosed by the Langerhans cells, macrophages and B cells. The altered autoantigens were further processed by the antigenpresenting cells and presented to the helper ⁄ inducer T cells in OLP patients' oral mucosa, regional lymph nodes and blood circulation. By the help of T cells, the antigen-specific activated B cells thus produced high levels of ANA in the local tissues and blood circulation of OLP patients. The locally produced autoantibodies in the interstitial fluid might diffuse into blood capillaries or be drained into the lymphatic vessels, which finally reached the blood circulation. This study showed that major EOLP, HCVA-positivity and TGA ⁄ TMA-positivity were the three major risk factors contributing to the possession of serum ANA in OLP patients. Major EOLP lesions have greater destruction of lesional oral mucosa and thus may release more nuclear antigens into the local tissues and blood circulation than minor EOLP or NEOLP lesions. In addition, HCVA-positive and TGA ⁄ TMA-positive OLP patients may have underlying chronic liver and autoimmune thyroid diseases, respectively. Therefore, they may have more nuclear antigens released in the local liver and thyroid tissues and blood circulation. By the similar mechanisms, these nuclear antigens may stimulate the antigen-specific activated B cells to produce more ANA. The locally secreted ANA together with the ANA produced in the blood circulation finally gave rise to significantly higher levels of serum ANA in OLP patients than in healthy control subjects. The disappearance of the anti-BCA antibodies and ANA after treatment-induced healing of the OLP lesions (6, 7) also suggests that the principal autoantigens come from the local OLP lesions.
Our previous study showed significantly higher frequencies of presence of HLA-DRw9 and HLATe22 antigens in Chinese OLP patients (18) and a significant association of HLA-Te22 with ANA in Chinese EOLP patients (19) . HLA-DRw9 has been found to have intimate relationship with autoimmune diseases such as Graves' disease, Hashimoto's thyroiditis, myasthenia gravis and insulin-dependent DM in Chinese (20) (21) (22) (23) . HLA-DRw9 in Chinese is even considered to take the place of HLA-DR3 in Caucasians in carrying the gene which predispose to the development of autoimmune diseases (18, 21) . Concomitant presence of OLP and underlying autoimmune thyroid disease trait in HLA-DRw9-positive Chinese patients may contribute to the possession of serum TGA or TMA in some of our OLP patients. In addition, an overlap of serum autoantibodies in the same individual is a common feature in patients with autoimmune disease. This study also showed an overlap of organ-specific and non-organ-specific serum autoantibodies in approximately 33-51% of OLP patients. These may partially explain why our OLP patients also had serum GPCA and why approximately 28% of our OLP patients have two or more kinds of autoantibody in their sera.
In conclusion, there are significantly higher frequencies of presence of ANA, GPCA, TGA and TMA in Chinese OLP patients. Major EOLP, TGA ⁄ TMA-positivity, and HCVA-positivity are significant risk factors to influence ANA-positivity in OLP patients. In addition, major EOLP and ANA-positivity had a significant influence on the possession of serum TGA ⁄ TMA in OLP patients. HCVA, anti-hepatitis C virus antibody; DM, diabetes mellitus; OLP, oral lichen planus; EOLP, erosive OLP; NEOLP, non-erosive OLP; ANA, anti-nuclear antibody; SMA, anti-smooth muscle antibody; AMA, anti-mitochondrial antibody, GPCA; anti-gastric parietal cell antibody; TMA; anti-thyroid microsomal antibodies; TGA, anti-thyroglobulin antibody.
